10 Breast Cancer Clinical Trials in Kansas City, KS (2026)

Q: How do I join a clinical trial in Kansas City?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you.

Recruiting Breast Cancer Studies in Kansas City

NCT00291096Recruiting

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

The overall goal of this project is to develop an integrative system of breast cancer risk assessment based on epidemiologic and biologic risk variables, as well as to develop or refine risk biomarker...

Kansas City, KS3,000 participantsCarol Fabian, MD

View Study Details

NCT02302742Recruiting

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes)....

Kansas City, KS3,000 participantsUniversity of Kansas Medical Center

View Study Details

NCT06827236Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participan...

Kansas City, KSPHASE1380 participantsBioNTech SE

View Study Details

NCT06184750Recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well establi...

Kansas City, KSPHASE2200 participantsNational Cancer Institute (NCI)

View Study Details

NCT07604571Recruiting

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients ...

Kansas City, KSPHASE1194 participantsNovartis Pharmaceuticals

View Study Details

NCT07220135Recruiting

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in...

Kansas City, KSPHASE2100 participantsUniversity of Kansas Medical Center

View Study Details

NCT05941520Recruiting

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for pa...

Kansas City, KSPHASE280 participantsNational Cancer Institute (NCI)

View Study Details

NCT07368998Recruiting

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-muta...

Kansas City, KSPHASE280 participantsHoffmann-La Roche

View Study Details

NCT06195306Recruiting

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of develop...

Kansas City, KSPHASE266 participantsNational Cancer Institute (NCI)

View Study Details

NCT07242118Recruiting

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

This phase II study evaluates SABR as non-operative treatment for women aged 65+ with ER-positive, HER2-negative breast cancer ≤5 cm and no lymph node involvement. Eligible patients, including those p...

Kansas City, KSNA18 participantsUniversity of Kansas Medical Center

View Study Details

About Breast Cancer Clinical Trials in Kansas City

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 10 breast cancer clinical trials recruiting participants in Kansas City, KS. These studies are seeking a combined 7,118 participants. Research is being sponsored by Carol Fabian, MD, University of Kansas Medical Center, BioNTech SE and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Kansas City — FAQ

Are there breast cancer clinical trials in Kansas City?

Yes, there are 10 breast cancer clinical trials currently recruiting in Kansas City, KS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Kansas City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.

Are clinical trials in Kansas City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 10 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated October 16, 2026 from ClinicalTrials.gov